Register

Login

Vet Times logo
+
  • View all news
  • Vets news
  • Vet Nursing news
  • Business news
  • + More
    • Videos
    • Podcasts
    • Crossword
  • View all clinical
  • Small animal
  • Livestock
  • Equine
  • Exotics
  • Job Seekers
  • Recruiters
  • Career Advice
About
Contact Us
For Advertisers
NewsClinicalJobs
Vet Times logo

Vets

All Vets newsSmall animalLivestockEquineExoticWork and well-beingInternational

Vet Nursing

All Vet Nursing newsSmall animalLivestockEquineExoticWork and well-beingOpinion

Business

All Business newsHuman resourcesBig 6SustainabilityFinanceDigitalPractice profilesPractice developments

+ More

VideosPodcastsDigital EditionCrossword

The latest veterinary news, delivered straight to your inbox.

Choose which topics you want to hear about and how often.

Vet Times logo 2

About

The team

Advertise with us

Recruitment

Contact us

Vet Times logo 2

Vets

All Vets news

Small animal

Livestock

Equine

Exotic

Work and well-being

International

Vet Nursing

All Vet Nursing news

Small animal

Livestock

Equine

Exotic

Work and well-being

Opinion

Business

All Business news

Human resources

Big 6

Sustainability

Finance

Digital

Practice profiles

Practice developments

Clinical

All Clinical content

Small animal

Livestock

Equine

Exotics

Jobs

All Jobs content

Job Seekers

Recruiters

Career Advice

More

All More content

Videos

Podcasts

Digital Edition

Crossword


Terms and conditions

Complaints policy

Cookie policy

Privacy policy

fb-iconinsta-iconlinkedin-icontwitter-iconyoutube-icon

© Veterinary Business Development Ltd 2026

IPSO_regulated

27 Feb 2026

VMD approves pruritus treatment Numelvi in UK

MSD Animal Health product, previously available in Europe, is only second-generation JAK inhibitor for pruritus associated with allergic dermatitis in dogs.

author_img

Vet Times

Job Title



VMD approves pruritus treatment Numelvi in UK

The only second-generation Janus kinase (JAK) inhibitor treatment for allergic dermatitis-associated  pruritus in dogs has been approved for use in the UK.

Numelvi from MSD Animal Health, featuring the atinvicitinib molecule, is the first and only second-generation JAK inhibitor indicated for use from six months (and 3kg).

The once-daily POM-V tablet is described as at least 10-times more selective for JAK1 than other family enzymes1, so therefore “has has very little to no effect on cytokines involved in haematopoiesis or immune function that are dependent on JAK2 or the other JAK family members”.

Indications

Numelvi is indicated for the treatment of pruritus associated with allergic dermatitis, including atopic dermatitis, as well as the clinical manifestations of atopic dermatitis in dogs

The product, which was available in the EU in the autumn, had been awaiting VMD approval for use in the Great Britain market.

Victoria Miles, companion animal director – Great Britain for MSD Animal Health, said: “Allergic dermatitis is a common condition that causes distress and discomfort for so many dogs.

“By combining targeted JAK1 selectivity with clinically proven efficacy in a once daily regimen, Numelvi helps make itch relief simple for dogs, pet owners and the veterinarians treating them.”

Selectivity

Specialist veterinary dermatologist Sue Paterson said: ““Treating canine allergic dermatitis means offering treatment which relieves itch and inflammation, whilst managing any unwanted side effects. We want to inhibit JAK1 to reduce itch and inflammation, while having little to no effect on other JAK family members.”

And fellow specialist Debbie Gow added: “The high selectivity for JAK1 contributes to the favourable safety profile of Numelvi.”

To mark the launch, a lunch-and-learn digital event, in partnership with The Webinar Vet, will take place on 26 March, with organisers hopeful of setting a Guinness World Record for a veterinary educational launch event.

Reference

1. Numelvi summary of product characteristics.